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onset  of  reperfusion  in  acute  myocardial  infarction:
Results  of  the  randomized  Intra-Co-EpoMI  trial
Administration  intracoronaire  de  darbépoétine-alpha  au  moment  de  la
reperfusion  au  cours  de  l’infarctus  aigu  du  myocarde  :  résultats  de  l’essai
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Summary
Background.  —  Several  trials  investigating  erythropoietin  as  a  novel  cytoprotective  agent  in
myocardial  infarction  (MI)  failed  to  translate  promising  preclinical  results  into  the  clinical
setting. These  trials  could  have  missed  crucial  events  occurring  in  the  ﬁrst  few  minutes  of
reperfusion.  Our  study  differs  by  earlier  intracoronary  administration  of  a  longer-acting  eryth-
ropoietin  analogue  at  the  onset  of  reperfusion.
Aim.  —  To  evaluate  the  ability  of  intracoronary  administration  of  darbepoetin-alpha  (DA)  at  the
very onset  of  the  reperfusion,  to  decrease  infarct  size  (IS).
Methods.  —  We  randomly  assigned  56  patients  with  acute  ST-segment  elevation  MI  to  receive
an intracoronary  bolus  of  DA  150  g  (DA  group)  or  normal  saline  (control  group)  at  the  onset  of
reﬂow obtained  by  primary  percutaneous  coronary  intervention  (PCI).  IS  and  area  at  risk  (AAR)
were evaluated  by  biomarkers,  cardiac  magnetic  resonance  (CMR)  and  validated  angiographical
scores.
Results. —  There  was  no  difference  between  groups  regarding  duration  of  ischemia,  Thrombo-
lysis in  Myocardial  Infarction  ﬂow  grade  at  admission  and  after  PCI,  AAR  size  and  extent  of  the
collateral circulation,  which  are  the  main  determinants  of  IS.  The  release  of  creatine  kinase  was
not signiﬁcantly  different  between  the  two  groups  even  when  adjusted  to  AAR  size.  Between
3—7 days  and  at  3  months,  the  area  of  hyperenhancement  on  CMR  expressed  as  a  percentage
of the  left  ventricular  myocardium  was  not  signiﬁcantly  reduced  in  the  DA  group  even  when
adjusted  to  AAR  size.
Conclusion.  —  Early  intracoronary  administration  of  a  longer-acting  erythropoietin  analogue  in
patients  with  acute  MI  at  the  time  of  reperfusion  does  not  signiﬁcantly  reduce  IS.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Plusieurs  essais  qui  ont  étudié  l’érythropoïétine  (EPO)  comme  un  nouvel  agent
protecteur  lors  de  l’infarctus  du  myocarde  (IDM),  ont  échoué  à  traduire  en  clinique  les  études
précliniques  prometteuses.  Ces  essais  pourraient  avoir  laissé  de  côté  des  évènements  cruciaux
au cours  des  premières  minutes  de  la  reperfusion.  Notre  étude  diffère  par  une  administration
plus précoce,  intracoronaire  d’une  EPO  à  longue  durée  d’action,  au  moment  de  la  reperfusion.
Objectifs.  —  L’objectif  de  cet  essai  était  d’évaluer  l’intérêt  de  la  darbépoétine-alpha  (DA)
intracoronaire  administrée  précocement  à  la  reperfusion  pour  diminuer  la  taille  de  l’IDM.
Méthodes.  — Nous  avons  randomisé  56  patients  avec  IDM  aigu  avec  sus-élévation  du  segment  ST,
pour recevoir  soit  un  bolus  intracoronaire  de  150  g  de  darbépoétine-alpha  (groupe  DA)  ou  du
sérum physiologique  (groupe  témoin)  au  moment  de  la  reperfusion  obtenue  par  angioplastie
primaire (PCI).  L’aire  à  risque  et  la  taille  de  l’infarctus  ont  été  évalués  par  des  biomarqueurs,
une imagerie  par  résonance  magnétique  (IRM)  et  des  scores  angiographiques  validés.
Résultats.  —  Il  n’y  avait  pas  de  différence  entre  les  deux  groupes  en  termes  de  durée  d’ischémie,
de ﬂow  TIMI  à  l’admission  et  après  angioplastie,  d’aire  à  risque  ou  encore  de  collatéralité,  qui
sont les  principaux  déterminants  de  la  taille  de  l’infarctus.  La  libération  de  CK  n’était  pas
signiﬁcativement  différente  entre  les  deux  groupes  même  après  ajustement  sur  la  taille  de
l’aire à  risque.  Après  trois  à  sept  jours  et  à  trois  mois,  l’aire  du  rehaussement  à  l’IRM  exprimée
comme un  pourcentage  du  ventricule  gauche  n’était  pas  signiﬁcativement  réduit  dans  le  groupe
DS, même  après  ajustement  sur  l’aire  à  risque.
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Conclusions.  —  L’administration  précoce  intracoronaire  d’une  EPO  de  longue  durée  d’action
chez de  patients  avec  IDM  aigu,  au  moment  de  la  reperfusion  ne  réduit  pas  signiﬁcativement  la
taille de  l’IDM.
©  2012  Elsevier  Masson  SAS.  Tous  droits  réservés.
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After  the  patients  gave  informed  consent,  they  were  ran-Background
Acute  myocardial  infarction  (MI)  is  a  leading  cause  of  death
worldwide.  In  patients  that  survive  the  immediate  event,
infarct  size  (IS)  is  the  main  determinant  of  further  prognosis
[1].  Rapid  reperfusion  of  the  ischemic  myocardium  remains
the  best  treatment  for  limiting  IS  and  further  complications
[2,3].  However,  recent  evidence  supports  the  idea  that
reperfusion  itself  has  the  potential  to  initiate  additional
lethal  injury  [4—6].  New  strategies  that  directly  target  the
reperfusion  phase  by  adding  adjunct  reperfusion  therapies
could  further  reduce  IS  and  improve  clinical  outcomes  of
acute  MI  [7,8].
Erythropoietin  (EPO),  a  cytokine  synthesized  by  the
kidney  in  response  to  hypoxia,  is  commonly  used  in  the  treat-
ment  of  the  anaemia  of  chronic  renal  failure  [9].  Beyond  its
well-known  haematopoietic  action,  EPO  inhibits  apoptosis
and  activates  prosurvival  kinases,  such  as  PI3  kinase-Akt,
in  adult  cardiomyocytes  exposed  to  hypoxic  injury  [10—12].
Several  reports  indicate  that  administration  of  recombinant
EPO  during  prolonged  ischemia  or  at  the  time  of  reperfusion
reduces  IS  and  improves  cardiac  function  in  animal  models
of  reperfused  MI  [10,11,13—15].  All  these  experimental  data
suggest  that  EPO  may  be  a  good  candidate  for  an  adjunct  to
reperfusion  in  MI  patients.
However,  several  recent  clinical  trials,  designed  to  inves-
tigate  the  safety  and  efﬁcacy  of  EPO  in  patients  with  MI,
have  already  been  published  with  negative  or  inconclusive
results  [16—22].  In  these  trials,  the  timing  of  the  cardiopro-
tective  strategy  could  have  missed  crucial  events  that  occur
in  the  ﬁrst  few  minutes  of  myocardial  reperfusion.  Numer-
ous  studies  performed  during  the  past  two  decades  testing
new  cardioprotective  strategies  have  already  failed  to  trans-
late  promising  laboratory  research  into  the  clinical  setting.
Recently,  the  UCL-Hatter  Cardiovascular  Institute  6th  Inter-
national  Cardioprotection  Workshop  with  the  Working  Group
of  Cellular  Biology  of  the  Heart  of  the  European  Society  of
Cardiology  and  the  2010  National  Heart  Lung  and  Blood  Insti-
tute  Workshop  have  published  recommendations  in  order  to
facilitate  the  translation  of  novel  cardioprotective  strate-
gies  [23].  The  duration  of  ischemia,  the  Thrombolysis  In
Myocardial  Infarction  (TIMI)  ﬂow  grade  at  admission  and
after  reopening  of  the  culprit  coronary  artery,  the  size  of  the
area  at  risk  (AAR),  the  extent  of  the  collateral  circulation
and  last  but  not  least  the  optimal  timing  of  the  applica-
tion  of  the  drug  are  key  issues  that  need  to  be  addressed  in
IS  reduction  trials.  To  protect  the  myocardium  from  reper-
fusion  injury,  the  drug  must  be  active  during  the  ﬁrst  minutes
of  reperfusion.  However,  we  do  not  know  for  how  long  the
exposure  to  the  drug  should  continue  in  order  to  optimize
the  prevention  of  myocardial  reperfusion  injury.The  objective  of  the  present  study  was  to  deter-
mine  whether  the  early  intracoronary  administration  of
darbepoetin-alpha  (DA),  a  long-acting  analogue  of  EPO,  at
d
g
che  onset  of  reperfusion  reduces  IS  in  patients  with  ongoing
cute  MI.
ethods
rial
he  Intra-Co-EpoMI  Trial  was  a  prospective  multicentre
andomized  single-blinded  controlled  trial.  The  trial  was
esigned,  the  data  were  collected  and  analysed,  and  the
anuscript  was  written  solely  by  the  authors.  DA  for  the  trial
as  purchased  with  institutional  grant  support;  the  manu-
acturer  had  no  role  in  the  study.  The  trial  was  performed
ccording  to  the  Declaration  of  Helsinki  (revised  version  of
omerset  West,  Republic  of  South  Africa,  1996),  the  Euro-
ean  Guidelines  of  Good  Clinical  Practice  (version  11,  July
990)  and  French  laws.  The  study  protocol  was  approved
y  the  ethics  committee  of  the  institution  of  the  princi-
al  investigator  (C.P.)  acting  on  behalf  of  all  the  institutions
nvolved  in  this  trial.  The  protocol  was  accepted  on  01  July
008.  All  subjects  gave  written  informed  consent  before
nclusion.
tudy population
ale  and  female  patients  aged  >  18  years  who  presented
ithin  12  hours  of  onset  of  chest  pain,  had  ST-segment  eleva-
ion  >  0.1  mV  in  at  least  two  contiguous  leads  and  for  whom
he  clinical  decision  was  made  to  treat  with  PCI  were  eligible
or  enrolment.  Patients  were  eligible  for  the  study  whether
hey  were  undergoing  primary  PCI  or  rescue  PCI.  The  culprit
oronary  artery  had  to  be  occluded  at  the  time  of  admission
TIMI  ﬂow  grade  0)  and  had  to  be  adequately  reperfused
TIMI  2—3  ﬂow  grade)  after  PCI.
Patients  with  cardiac  arrest,  ventricular  ﬁbrillation,
ardiogenic  shock,  stent  thrombosis  or  previous  MI  were
ot  included.  Patients  with  evidence  of  coronary  collater-
ls  (Rentrop  grade  >  1)  supplying  the  region  at  risk  were
xcluded  from  the  study.  Also  excluded  were  patients
ith  known  hypersensitivity  to  EPO,  known  polyglobulia,
ncontrolled  hypertension  or  thromboembolic  disease,  con-
raindication  to  cardiac  magnetic  resonance  (CMR)  imaging,
atients  already  treated  with  EPO  or  cyclosporine  and
omen  who  were  pregnant  or  who  were  of  childbearing  age
nd  were  not  using  contraception.
xperimental protocolomly  assigned  to  either  the  control  group  or  the  DA
roup.  Randomization  was  performed  with  the  use  of  a
omputer-generated  randomization  sequence.  Numbered,
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ealed  envelopes  that  contained  the  study  group  assignment
ere  distributed  to  each  catheterization  laboratory.
All  patients  received  clopidogrel  600  mg  orally,  aspirin
00  mg  and  unfractionated  heparin  with  or  without  a  gly-
oprotein  IIb/IIIa  inhibitor  intravenously  prior  to  PCI.  In
he  treated  group,  the  patients  received  an  intracoro-
ary  bolus  injection  of  DA  150  g  (Amgen© Inc.,  Thousand
aks,  CA,  USA)  at  the  onset  of  reperfusion  (i.e.  less  than
 minute  after  reopening  of  the  culprit  coronary  artery).  The
atients  in  the  control  group  received  an  equivalent  vol-
me  of  normal  saline.  The  dose  of  DA  was  chosen  based  on
xperimental  data  and  previous  clinical  studies  [24].  The  PCI
rocedure  was  then  completed  according  to  the  physician’s
udgment.  Postinterventional  therapy  consisted  of  clopido-
rel  75  mg/day  for  at  least  1  year.  Aspirin  75  mg/day  was
ecommended  indeﬁnitely.  Other  cardiac  medications  were
rescribed  at  the  discretion  of  the  treating  physician.
The  patient  and  the  assessors  of  data  analysis  and  clinical
utcomes  were  blinded  to  the  treatment  allocation.
ndpoints
he  primary  endpoint  was  MI  size  as  determined  by  creatine
inase  (CK)  release  obtained  at  admission  and  repeated  over
he  following  3  days,  as  described  previously  [7,8].  Blood
amples  were  taken  at  admission,  every  4  hours  after  open-
ng  of  the  coronary  artery  during  day  1  and  every  6  hours  on
ays  2  and  3.  Area  under  the  curve  (arbitrary  units)  of  serum
K  release  (Beckman  Kit,  expressed  in  IU/L)  was  measured
n  each  patient  by  computerized  planimetry  (Image  J  1.29x)
nd  used  as  a  surrogate  marker  of  infarct  size.  The  principal
econdary  endpoint  was  MI  size  as  assessed  between  3  and
 days  and  at  3  months  (±  1  week)  postinfarction  by  the  area
f  hyperenhancement  on  CMR  expressed  as  a  percentage  of
he  left  ventricular  myocardium  [7].
ther endpoints
ajor  adverse  events  that  occurred  during  the  initial  hos-
italization  and  3  months  after  acute  MI,  including  death,
eart  failure,  acute  MI,  stroke,  recurrent  ischemia,  the  need
or  repeat  revascularization,  renal  or  hepatic  insufﬁciency,
ascular  complications  and  bleeding,  were  recorded.
ngiography
oronary  angiography  was  performed  using  standard  tech-
iques.  All  images  were  reanalysed  in  a  core  laboratory
eparately  by  two  senior  interventional  cardiologists  in  a
linded  fashion  to  classify  TIMI  ﬂow  before  and  after  PCI.
For  each  patient,  the  size  of  the  AAR  (i.e.  the
yocardium  supplied  by  the  occluded  coronary  artery)  was
ssessed  by  two  angiographical  scores.  The  modiﬁed  ver-
ion  of  the  angiographical  APPROACH  score  is  based  on
athological  and  necropsy  studies  evaluating  the  amount  of
yocardium  supplied  by  different  coronary  arteries  [25].
he  angiographical  BARI  score  is  based  upon  an  individ-
alized  assessment  of  the  length  and  calibre  of  coronary
rteries  for  the  assessment  of  the  jeopardized  myocardium
26].  AAR  was  expressed  as  a  percentage  of  the  left  ventri-
ular  myocardium.
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MR imaging
MR  imaging  was  performed  between  3  and  7  days  and
epeated  at  3  months  (±  1  week)  using  a  1.5  T  scanner
Avanto-Siemens,  Erlangen,  Germany)  with  infusion  of
.5  mL/kg  of  gadoterate  meglumine  (Gd-DOTA,  Dotarem;
uerbet  SA,  Paris,  France).  T2-weighted  CMR  was  per-
ormed  by  encompassing  the  left  ventricle  in  cardiac
hort-axis,  vertical  long-axis  and  four-chamber  directions
ith  a  dark-blood  T2-weighted  short  tau  inversion  recovery
ast  spin-echo  sequence.  Imaging  variables  were  repeti-
ion  time,  2  heartbeats;  echo  time,  100  ms;  turbo  factor
3;  ﬁeld  of  view,  350  mm;  slice  thickness,  8  mm.  Both  cine
nd  contrast-enhanced  short-axis  CMR  images  were  pre-
cribed  every  10  mm  (slice  thickness,  6  mm)  from  base  to
pex.  In-plane  resolution  was  typically  1.2  ×  1.8  mm.  Cine
MR  was  performed  using  a  steady-state  free-precession
equence.  Contrast  CMR  images  were  acquired  on  average
—10  minutes  after  contrast  (power  injector)  using  a  seg-
ented  inversion  recovery  gradient  echo  three-dimensional
echnique,  constantly  adjusting  inversion  time  to  null
ormal  myocardium,  and  acquisition  in  phase  sensitive
nversion  recovery  of  10  slices  on  a  single  breath-hold.
herefore,  total  acquisition  time  was  between  30  and
0  minutes  for  all  cine  and  contrast  images.  All  patients  were
ble  to  tolerate  lying  ﬂat  in  the  magnet  until  the  examina-
ion  was  completed.  The  contrast  dose  was  0.1  mmol/kg.
MR analysis
ll  images  were  evaluated  separately  by  two  blinded
bservers  (seniors  radiologists)  and  were  analysed  on  an
fﬂine  workstation  (Argus,  Siemens  AG,  Munich,  Germany).
The  AAR  was  quantiﬁed  on  the  T2-weighted  images
y  delineation  of  myocardium  with  hypersignal  intensity
rom  the  CMR  imaging  performed  between  3  and  7 days
ostinfarction,  and  the  IS  by  delineation  of  hyperenhance-
ent  on  the  contrast-enhanced  CMR  performed  between
 and  7  days  and  at  3  months  (±  1  week)  postinfarction.
he  hypoenhanced  surface  of  microvascular  obstruction  and
ypointense  T2-weighted  signal  within  the  area  of  increased
ignal  intensity  (haemorrhagic  infarction)  were  included
n  the  IS.  The  transmurality  degree  of  MI  was  quantiﬁed
n  four  different  groups  (extent  of  contrast  enhance-
ent/normal  myocardium:  0—25%;  25—50%;  50—75%;  >  75%
f  transmurality).  Areas  of  hyperintense  T2-weighted  signal
nd  late  gadolinium  enhancement  on  contrast  enhancement
equences  were  reported  separately  on  a  17-segment  model
f  the  left  ventricle.  IS  and  AAR  results  were  expressed  as  a
ercentage  of  the  total  segment  area.  The  IS/AAR  ratio  was
alculated  as  follows:  number  of  segments  with  IS/number
f  segments  with  T2-weighted  hypersignal.
tatistical analysis
he  number  of  patients  to  be  included  was  calculated  using
he  following  hypotheses:  an  infarct  size  of  40%  (reported
o  the  area  at  risk);  a  reduction  of  15%  in  the  treated  group
standard  error  of  mean  =  7.5%),  with    =  0.05,    =  0.20;  and
0%  without  a complete  follow-up  or  without  primary  end-
oint  evaluation.  On  this  basis  it  was  necessary  to  include
5  patients.
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provided reasons. TIMI: thrombolysis in myocardial infarction.
The  data  processing  was  performed  using  SAS  software
package  version  9.1.  A  general  descriptive  analysis  was  done
for  each  variable  of  the  study.  The  distribution  of  quali-
tative  variables  between  groups  was  compared  using  the
chi-square  test.  If  one  of  the  calculated  frequencies  in  the
contingency  table  did  not  exceed  5,  Fisher’s  exact  test  was
performed.  Quantitative  variables  were  compared  using  the
Wilcoxon-Mann-Whitney  test  as  the  variables  were  not  nor-
mally  distributed.
The  Kendall  test  was  used  for  the  correlations  between
the  areas  at  risk.  The  area  under  the  curve  was  not  calcu-
lated  when  there  were  two  successive  missing  data  points.
When  there  was  only  one  missing  dose,  its  value  was  esti-
mated  by  linear  regression  on  convex-transformed  data.
Results
Characteristics of the population
Between  December  2008  and  November  2009,  56  patients
(10  women,  46  men)  59  ±  13  years  of  age  were  random-
ized  in  four  academic  medical  centres  (Clermont-Ferrand,
Nîmes,  Marseille  and  Montpellier):  30  received  DA  and  26
received  placebo  (Fig.  1).  Five  patients  were  excluded  from
the  study:  one  because  reperfusion  had  occurred  before  PCI
(TIMI  2  ﬂow  grade  on  the  initial  coronary  angiography)  and
four  because  of  Rentrop  2  and  3  collateral  coronary  circula-
tion  to  the  AAR.  Table  1  summarizes  the  main  characteristics
of  the  randomized  population.  Major  risk  factors,  angio-
graphical  ﬁndings,  left  ventricular  ejection  fraction  (LVEF)
and  treatments  were  similar  between  the  two  groups  except
for  hypertension  (P  =  0.02).
Main determinants of ISThere  was  no  difference  between  the  two  groups  with  regard
to  duration  of  ischemia  (i.e.  time  from  onset  of  chest  pain
to  reperfusion)  (P  =  0.53)  (Table  1).
l
t
s
ﬁarbepoetin-alpha (DA) or control and patients who dropped out for
The  two  groups  were  also  similar  with  respect  to  the
ize  of  the  AAR,  whatever  the  score  used  (P  =  0.37  with  the
MR  score;  P  =  0.13  with  the  BARI  score;  P  =  0.32  with  the
odiﬁed  APPROACH  score)  (Table  2).
All  the  patients  had  a  Rentrop  grade  ≤  1  and  TIMI  2—3
ow  grade  was  achieved  in  all  patients  after  PCI  (Table  1).
nzymatic IS
he  peak  serum  CK  concentration  after  reperfusion  was  not
igniﬁcantly  different  in  the  DA  group  compared  with  in  the
ontrol  group  (median  2048  vs.  2290  arbitrary  units,  respec-
ively;  P  =  0.48)  (Fig.  2A).  In  a  subgroup  of  34  patients,  the
edian  area  under  the  curve  for  serum  CK  release  after
eperfusion  was  3,328,418  arbitrary  units  in  the  DA  group
nd  3,959,095  in  the  control  group  (Fig.  2B).  This  difference
as  not  signiﬁcant  (P  =  0.08).
The  two  groups  remained  similar  when  the  peak  serum  CK
evel  was  adjusted  to  the  size  of  the  AAR,  whatever  the  score
sed  (P  =  0.77  with  the  CMR  score;  P  =  0.26  with  the  BARI
core;  P  =  0.29  with  the  modiﬁed  APPROACH  score)  (Fig.  3A).
imilar  results  were  also  obtained  when  the  median  area
nder  the  curve  for  serum  CK  release  after  reperfusion  was
djusted  to  the  size  of  the  AAR,  whatever  the  score  used
P  =  0.62  with  the  CMR  score;  P =  0.06  with  the  BARI  score;
 =  0.05  with  the  modiﬁed  APPROACH  score)  (Fig.  3B).
S assessed by CMR
etween  3  and  7  days  after  infarction,  the  area  of  hyper-
nhancement  on  CMR  expressed  as  a  percentage  of  the
eft  ventricular  myocardium  was  not  signiﬁcantly  differ-
nt  in  the  DA  group  compared  with  in  the  control  group
median  29.89%  vs.  29.05%,  respectively;  P  =  0.60)  (Fig.  4A).
he  two  groups  remained  similar  when  the  area  of  hyper-
nhancement  on  CMR  expressed  as  a  percentage  of  the
eft  ventricular  myocardium  was  adjusted  to  the  size  of
he  AAR,  whatever  the  score  used  (P  =  0.25  with  the  CMR
core;  P  =  0.80  with  the  BARI  score;  P  =  0.75  with  the  modi-
ed  APPROACH  score)  (Fig.  4B).
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Table  1  Baseline  characteristics  of  the  study  population.
Characteristics EPO group
(n  = 27)
Control group
(n = 24)
P
Age (years) 62.77 ± 12.61 55.13 ± 11.84 0.03
Men 20 21 0.30
BMI (kg/m2) 26.70 ± 3.95 25.96 ± 4.17
Hypertension 13 4 0.02
Tabagism 15 19 0.07
Familial history of coronary artery disease 10 8 0.78
Diabetes 6 1 0.10
Overweight 14 11 0.66
Dyslipidaemia 14 9 0.30
Heart rate on  admission (bpm) 73.04 ± 12.42 68.08 ± 12.91 0.20
Angiographical ﬁndings
Ischemia  time (minutes) 233.73 ±  174.49 308.57 ± 282.53 0.53
Infarct-related artery
Common trunk  0/27 0/24
Left descending artery
Culprit  lesion 10/27 7/24 0.43
Successful angioplasty 10/10 6/7 0.35
Circumﬂex
Culprit lesion 5/27 7/24 0.08
Successful angioplasty 5/5  7/7 0.74
Right coronary artery
Culprit  lesion 9/27 10/24 0.97
Successful angioplasty 8/9 10/10 0.75
Collaterality (Rentrop ≥ 2) 0 0 1.0
LVEF (%)a 51.54 ± 11.07 48.88 ± 10.90 0.45
Treatment before  PCI
Aspirin  19 16 0.32
Clopidogrel 15 15 0.85
Glycoprotein IIb/IIIa inhibitor 1  1 1.0
Heparin 16 12 0.17
LMWH 1 4 0.35
Oral anticoagulant 0 0
Statin 1 1 1.0
Beta-blocker 1 1 1.0
ACE inhibitor 0 0
ARI 1 1 1.0
Anti-inﬂammatory drugs 0 0
Treatment at time of PCI
Aspirin 3 8 0.08
Clopidogrel 2 2 1.0
Glycoprotein IIb/IIIa inhibitor 10 12 0.46
Heparin 3 8 0.16
LMWH 0 1 0.49
Oral anticoagulant 0 0
Statin 1 1 0.49
Beta-blocker 0 1 0.49
ACE inhibitor 1 0 1.0
ARI 0 1 0.44
Anti-inﬂammatory drugs 0 0
Data are mean ± standard deviation, number or number/total number. ACE: angiotensin-converting enzyme; ARI: angiotensin II receptor
inhibitor; BMI, body mass index; EPO: erythropoietin; LMWH: low molecular weight heparin; LVEF, left ventricular ejection fraction; PCI:
percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; TIMI: thrombolysis in myocardial infarction.
a First evaluation between third and seventh day after STEMI.
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Table  2  Area  at  risk  among  patients,  assessed  by  three  different  methods.
Scoring  method  Total  n  EPO  group  (n  =  27)  Control  group  (n  =  24)  P
AARa n  AARa n
CMR  scan  T2  hypersignal  38  39.00  ±  13.4  19  43.95  ±  17.3  19  0.38
BARI  score 49  29.41  ±  6.79 26  26.81  ±  6.07  23  0.13
APPROACH  score 49  28.58  ±  6.76 26  27.54  ±  8.22  23  0.32
Data are mean ± standard deviation. AAR: area at risk; CMR: cardiac magnetic resonance; EPO: erythropoietin.
a Expressed as a percentage of the left ventricular myocardium.
Figure 2. Primary endpoint: level of serum creatine kinase (CPK)
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din patients treated with darbepoetin-alpha (DA) and in patients in
the control group after successful reperfusion: (A) peak and (B) area
under the curve (AUC). NS: not signiﬁcant.
At  3  months  after  infarction,  the  median  area  of  hyper-
enhancement  on  CMR  expressed  as  a  percentage  of  the  left
ventricular  myocardium  was  26.06%  in  the  DA  group  and
28.01%  in  the  control  group;  this  difference  was  not  signif-
icant  (P  =  0.63)  (Fig.  5A).  The  two  groups  remained  similar
when  the  area  of  hyperenhancement  on  CMR  expressed  as  a
percentage  of  the  left  ventricular  myocardium  was  adjusted
to  the  size  of  the  AAR,  whatever  the  score  used  (P  =  0.21  with
the  CMR  score;  P  =  0.51  with  the  BARI  score;  P  =  0.64  with  the
modiﬁed  APPROACH  score)  (Fig.  5B).Adverse clinical events
During  the  initial  hospitalization,  seven  serious  adverse  clin-
ical  events  were  recorded  in  the  DA  group:  one  death
m
c
in  a  patient  with  a  large  anterior  infarct,  three  cases  of
eversible  thrombocytopenia  in  patients  on  eptiﬁbatide,  one
pisode  of  atrial  ﬁbrillation,  one  acute  stent  thrombosis
nd  one  local  haematoma.  No  serious  adverse  event  was
eported  in  the  control  group.
During  non-hospital  follow-up,  one  death  was  recorded
n  the  DA  group  (unknown  metastasized  colon  cancer
iagnosed  during  the  initial  hospitalization).  There  were  two
dverse  clinical  events  in  the  control  group:  one  episode  of
entricular  ﬁbrillation  and  one  symptomatic  hypotension.
iscussion
n  this  small-sized  clinical  trial,  which  was  designed  in  com-
lete  accordance  with  the  Hatter  Workshop  and  the  National
eart  Lung  and  Blood  Institute  Workshop  Recommendations,
he  early  intracoronary  administration  of  a  longer-acting
PO  analogue  in  patients  with  acute  MI  at  the  time  of  reper-
usion  was  not  associated  with  a  smaller  IS,  assessed  by
easuring  both  the  release  of  cardiac  biomarkers  and  the
rea  of  hyperenhancement  on  CMR  postinfarction.
DA  is  a  long-acting  EPO  analogue  with  favourable  effects
n  IS  and  postMI  remodelling  in  rodents  (mice  [27—33],
ats  [15,30—32,34—39]  or  rabbits  [40—42]). Baker  et  al.
emonstrated  that  single  intravenous  DA  treatment  con-
ers  immediate  and  sustained  cardioprotection  in  rats  when
dministered  after  the  onset  of  ischemia  and  at  the  start
f  reperfusion  [34].  They  observed  reduced  myocardial
ecrosis  in  a  dose-dependent  manner.  Optimal  protection
as  manifest  at  a  dose  of  2.5  g/kg.  In  a clinically  rel-
vant  porcine  model  of  ischemia-reperfusion,  intravenous
dministration  of  a  larger  dose  of  DA  (30  g/kg)  5  minutes
rior  to  reperfusion  led  to  increased  capillary  density,
ecreased  interstitial  ﬁbrosis  and  signiﬁcant  regional  func-
ional  improvement  despite  a  lack  of  reduction  in  the  IS  [14].
n  the  ﬁrst  pilot  clinical  study,  Lipsic  et  al.  demonstrated
hat  one  bolus  of  DA  300  g  administered  intravenously
efore  primary  PCI  was  safe  and  well  tolerated  [24].  How-
ver,  patients  enrolled  in  the  main  clinical  trials  that  have
een  recently  published  received  either  epoetin  alpha  or
poetin  beta  [16—22]. These  studies  concluded  that  EPO
dministration  in  acute  MI  patients  was  safe  except  for  the
rials  with  the  highest  dose  of  EPO,  which  showed  a  ten-
ency  towards  an  increased  incidence  of  adverse  events  and
icrovascular  obstruction  [16—18].
The  chosen  dose  should  obviously  be  discussed.  In  these
linical  trials,  doses  were  lower  than  those  administered
n  experimental  studies  (3000—5000  IU/kg  most  often).
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Figure 3. Level of serum creatine kinase (CPK) in patients treated
with darbepoetin-alpha (DA) and in patients in the control group
after successful reperfusion adjusted to the size of the area at
risk with three different scores (cardiac magnetic resonance [CMR]
score, BARI score and modiﬁed APPROACH score): (A) peak and; (B)
area under the curve (AUC). NS: not signiﬁcant.
Figure 4. a: area of hyperenhancement on cardiac magnetic
resonance (CMR) measured between 3 and 7 days after myocardial
infarction and expressed as a percentage of the left ventricular
myocardium in patients treated with darbepoetin-alpha (DA) and in
patients in the control group after successful reperfusion; b: area of
hyperenhancement on CMR adjusted to the size of the area at risk
with three different scores (CMR score, BARI score and modiﬁed
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ery  few  experimental  studies  focused  on  dose-response.
n  rats  receiving  darbepoetin  0.25—25  g/kg  intravenously,
5  minutes  before  ischemia,  the  optimal  dose  seemed  to
e  2.5  g/kg  (i.e.  175  g  in  a  man  weighing  70  kg)  [34].  In
linical  trials,  doses  ranged  from  30,000—60,000  IU,  roughly
00—1000  IU/kg  for  a  patient  weighing  70  kg,  except  one
mall  study  testing  a  low-dose  protocol  (6000  IU)  [21].  Only
wo  studies  adapted  the  dose  to  the  individual  weight
20,43],  so  that  could  introduce  an  additional  bias  in  other
rials.  None  of  the  studies  tested  several  different  doses.
ore  importantly,  the  doses  should  be  compared  with  cau-
ion,  as  different  routes  and  timings  of  administration  are
robably  even  more  important  as  regards  pharmacokine-
ics  and  molecular  targets.  In  our  study  we  chose  a  dose
y  analogy  with  experimental  models  and  previous  clinical
rials.  We  aimed  for  a  high-dose  to  provide  a  bolus  effect,
specially  as  the  intracoronary  route  was  favourable  for  this
urpose.  Nevertheless,  smaller  or  higher  doses,  or  even  rep-
titions  of  the  doses,  could  be  of  interest.
Intracoronary  administration  of  darbepoetin- at  onset  of  reperf
Figure 5. A. Area of hyperenhancement on cardiac magnetic res-
onance (CMR) measured 3 months after infarction and expressed as a
percentage of the left ventricular myocardium in patients treated
with darbepoetin-alpha (DA) and in patients in the control group
after successful reperfusion. B. Area of hyperenhancement on CMR
adjusted to the size of the area at risk with three different scores
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AAR.  A  recent  study  that  aimed  to  determine  the  effect  of(CMR score, BARI score and modiﬁed APPROACH score). NS: not
signiﬁcant.
The  timing  of  the  cardioprotective  strategy  is  critical
in  the  design  of  clinical  studies.  Although  available  data
are  surprisingly  sparse,  there  appears  to  be  a  consensus
regarding  the  fact  that  the  time  window  of  protection
is  quite  narrow  because  the  main  part  of  lethal  reper-
fusion  injury  takes  place  within  the  ﬁrst  minutes  of  reﬂow
after  prolonged  ischemia.  Protective  interventions  must  be
applied  either  intravenously  prior  to  the  opening  of  the
culprit  coronary  artery  or  locally  at  the  onset  of  reper-
fusion.  In  this  study,  we  chose  to  deliver  DA  early  via  the
intracoronary  route  at  onset  of  reﬂow  (i.e.  as  soon  as  we
got  an  angiographic  TIMI  ﬂow  grade  of  2  or  3  in  the  cul-
prit  coronary  artery)  in  order  to  obtain  a  local  peak  level
of  DA  <  1  minute  after  adequate  reperfusion.  Local  delivery
of  DA  via  the  coronary  arteries  may  increase  local  drug
concentration,  improve  drug  efﬁcacy  and  reduce  general
side  effects.  As  we  do  not  know  how  long  after  reﬂow  the
exposure  to  the  drug  should  continue,  the  administration
of  a  long-acting  drug  may  help  to  optimize  the  prevention
of  myocardial  injury.  It  is  important  to  note  that  EPO  was
p
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ntravenously  injected  from  several  minutes  to  several  hours
fter  PCI  in  most  previous  clinical  trials  (when  reperfusion
njury  has  already  occurred)  except  in  the  study  by  Lud-
an  et  al.,  in  which  it  was  injected  before  PCI  [16—22].
atients  in  whom  the  infarct-related  coronary  artery  has
pontaneously  recanalized  (TIMI  >  1)  should  also  be  system-
tically  excluded.  One  patient  was  withdrawn  from  our  study
ecause  reperfusion  had  occurred  before  PCI.  It  is  of  inter-
st  to  note  that  up  to  17%  of  patients  in  the  EPO/AMI-1  study
nd  30%  of  patients  in  the  REVIVAL-3  study  had  an  initial  TIMI
ow  grade  >  1  before  PCI  [19,20].
The  duration  of  ischemia,  the  amount  of  collateral  cir-
ulation  to  the  ischemic  tissue  and  the  size  of  the  AAR
re  the  main  determinants  of  the  IS.  In  our  study,  the
uration  of  ischemia  averaged  279  minutes  in  the  DA  group
ompared  with  236  minutes  in  the  control  group  (P  not
igniﬁcant)  and  was  similar  to  what  is  usually  seen  in  clini-
al  studies  investigating  cardioprotective  strategies  in  acute
I  [7,8,17—19,21,22].  Most  of  these  studies,  except  for  the
EVIVAL-3  study,  included  patients  who  presented  less  than
2  hours  following  the  onset  of  chest  pain.  The  presence  of
oronary  collateralization  to  the  jeopardized  myocardium
s  also  a  well-known  confounding  factor  in  the  measure  of
S.  Four  patients  with  visible  coronary  collaterals  on  angio-
raphy  at  admission  (Rentrop  grade  >  1)  were  excluded  from
ur  study.  This  important  issue  was  not  taken  into  account
n  previous  trials  designed  to  investigate  efﬁcacy  of  EPO  in
I  patients  [16—19,21,22]. The  AAR  represents  also  a  major
eterminant  of  the  ﬁnal  IS.  Both  the  BARI  score  and  the
odiﬁed  APPROACH  score  can  be  used  clinically  to  accu-
ately  estimate  the  anatomical  myocardium  AAR  in  patients
ith  acute  MI  [44].  T2-weighted  CMR  imaging  to  determine
yocardial  oedema  constitutes  an  emerging  surrogate  of
stimating  the  AAR  [45].  However,  it  is  of  interest  to  note
hat  the  AAR  was  not  measured  in  most  of  the  previous  clini-
al  trials,  except  in  the  studies  by  Ludman  et  al.  and  Prunier
t  al.,  in  which  the  AAR  was  assessed  by  CMR  and  angiogra-
hy  scores,  respectively  [16,20].  In  this  study,  IS  assessed  by
easuring  both  the  release  of  cardiac  biomarkers  and  the
rea  of  hyperenhancement  on  CMR  was  adjusted  to  the  size
f  the  AAR  using  three  different  scores  (i.e.  the  CMR  score,
he  BARI  score  and  the  modiﬁed  APPROACH  score).
tudy limitations
lthough  we  took  the  major  determinants  of  IS  into  consider-
tion  in  the  experimental  design  of  this  trial  in  accordance
ith  the  Hatter  Workshop  Recommendations,  the  present
tudy  still  has  several  limitations.  First,  it  was  a  single-
linded  trial.  Second,  it  was  a  study  examining  a  small
umber  of  patients.  Third,  the  EPO  group  was  signiﬁcantly
lder  and  more  patients  had  hypertension.  As  age,  hyper-
ension  and  left  ventricular  hypertrophy  might  interfere
ith  pharmacological  conditioning  [46],  these  limitations
ould  have  hampered  the  ability  to  detect  a  difference.
omorbidities  could  impact  on  the  myocardial  sensitivity
o  cardioprotective  strategies.  Fourth,  both  angiographical
nd  CMR  scores  have  limitations  for  the  assessment  of  theost-conditioning  on  myocardial  oedema  in  patients  with  ST-
egment  elevation  MI  suggested  that  the  CMR  score  might
nderestimate  the  AAR  in  the  treated  group  but  not  in  the
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[44  
ontrol  group,  leading  to  the  protective  effect  being  either
issed  or  underestimated  [20].  Fifth,  recruitment  lasted  for
 year,  introducing  probable  heterogeneity  in  clinical  prac-
ices,  but  such  difﬁculties  appear  frequently  in  this  kind
f  emergency  clinical  trial.  Finally,  myocardial  IS  estimated
rom  biomarkers  and  imaging  is  considered  only  as  a  surro-
ate  for  clinical  outcome.
onclusion
n  summary,  the  early  intracoronary  administration  of  a
onger-acting  EPO  analogue  in  patients  with  acute  MI  at  the
ime  of  reperfusion  does  not  signiﬁcantly  reduce  IS.
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